Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 16/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 11/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995707 | 1.00 | MAOB (0.51) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL27759010 | 0.91 | MAOB (0.44) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL3079121 | 0.91 | MAOB (0.44) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL27842888 | 0.91 | MAOB (0.44) | MAOBMAOAACHEBCHEADRA2B | |
| Tartaric Acid SCHEMBL30356997 | 0.84 | MAOB (0.36) | MAOBMAOAACHEBCHEADRA2B | |
| Cadaverine Tartrate SCHEMBL28970956 | 0.84 | MAOB (0.36) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL27564190 | 0.70 | HTR2A (0.38) | ADRA2BADRA2CADRA1AHTR6 | |
| SCHEMBL27788995 | 0.70 | HTR2A (0.36) | MAOBMAOAADRA2BADRA2CADRA1A | |
| SCHEMBL29004430 | 0.70 | SIGMAR1 (0.40) | ACHEBCHEADRA2BADRA2CADRA1A | |
| SCHEMBL7065657 | 0.70 | BCHE (0.46) | ACHEBCHEADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118141772-A | Ropinirole Luo Jia hydrochloride sulfonic acid rasagiline compound orally disintegrating controlled release tablet and preparation method thereof | 四川鲁徽制药有限责任公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-116082166-A | Preparation method of rasagiline mesylate | 上海复旦复华药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20110015274-A1 | FORM OF AN AMINOINDAN MESYLATE DERIVATIVE | MEDICHEM, S.A. (ES) | 2011-01-20 | — | — | US | disclosed |
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015274-A1 | FORM OF AN AMINOINDAN MESYLATE DERIVATIVE | RAB29, RAB6A, QDPR | MAOB 491/4885ADRA2B 524/4885ADRA2C 695/4885 |
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | RAB35, RAB7A, RAB10 | MAOB 2254/4885ADRA2B 343/4885ADRA2C 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.